We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 101 increasing their positions, 75 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more call options, than puts

Call options by funds: $89.5M | Put options by funds: $20.4M

114% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 29

83% more capital invested

Capital invested by funds: $3B → $5.5B (+$2.5B)

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

35% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 75

14% more funds holding

Funds holding: 236 → 268 (+32)

Holders
268
Holders Change
+32
Holders Change %
+13.56%
% of All Funds
5.8%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.28%
New
62
Increased
101
Reduced
75
Closed
29
Calls
$89.5M
Puts
$20.4M
Net Calls
+$69.1M
Net Calls Change
+$50.4M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$123M
2
PA
Perceptive Advisors
New York
+$88M
3
MWNA
Marshall Wace North America
New York
+$52.9M
4
ACA
Avoro Capital Advisors
New York
+$41.6M
5
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$33.4M

Top Sellers

1
RG
Redmile Group
California
-$114M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84M
3
Millennium Management
Millennium Management
New York
-$30.8M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$30.7M
5
BI
BVF Inc
California
-$27.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
101
Birchview Capital
Vermont
$4.1M – – –
Allianz Asset Management
102
Allianz Asset Management
Germany
$4.08M -$73.7K -3,540 -2%
AAI
103
Aequim Alternative Investments
California
$4.02M +$3.44M +165,000 New
Prudential Financial
104
Prudential Financial
New Jersey
$3.69M -$5.32M -255,530 -63%
UBS Group
105
UBS Group
Switzerland
$3.47M -$727K -34,909 -20%
Manulife (Manufacturers Life Insurance)
106
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.35M -$44.4K -2,132 -2%
AIG
107
American International Group
New York
$3.28M -$22.7K -1,089 -0.8%
PNC Financial Services Group
108
PNC Financial Services Group
Pennsylvania
$3.16M +$326K +15,670 +14%
HighTower Advisors
109
HighTower Advisors
Illinois
$3.01M +$637K +30,593 +33%
Marshall Wace
110
Marshall Wace
United Kingdom
$2.94M -$928K -44,559 -27%
Los Angeles Capital Management
111
Los Angeles Capital Management
California
$2.9M +$1.57M +75,525 +174%
Nisa Investment Advisors
112
Nisa Investment Advisors
Missouri
$2.9M – – –
CEP
113
Chicago Equity Partners
Illinois
$2.88M +$2.46M +118,145 New
Jane Street
114
Jane Street
New York
$2.82M +$2.41M +115,657 New
Legal & General Group
115
Legal & General Group
United Kingdom
$2.78M +$499K +23,971 +27%
Barclays
116
Barclays
United Kingdom
$2.69M +$1.83M +87,859 +390%
EAM
117
Erste Asset Management
Austria
$2.49M -$296K -14,200 -12%
State Board of Administration of Florida Retirement System
118
State Board of Administration of Florida Retirement System
Florida
$2.46M – – –
NSIM
119
North Star Investment Management
Illinois
$2.44M – – –
ProShare Advisors
120
ProShare Advisors
Maryland
$2.37M +$65.4K +3,143 +3%
QI
121
QS Investors
New York
$2.31M +$1.87M +89,952 +1,935%
EI
122
EAM Investors
California
$2.3M +$1.96M +94,275 New
Citigroup
123
Citigroup
New York
$2.29M -$5.39M -258,921 -73%
MIM
124
MetLife Investment Management
New Jersey
$2.22M – – –
Fisher Asset Management
125
Fisher Asset Management
Washington
$2.21M +$46.9K +2,251 +3%
3 4
5
6 7

ARRY Hedge Fund Activity: Q1 2019 in Review

268 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2019, worth a combined $5.5B — up 83% from $3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new ARRY positions and 29 closed out — a net gain of 33 holders — while 101 added to existing stakes and 75 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was Redmile Group, cutting an estimated $114M.

  • 268 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2019, up from 236 in Q4 2018.
  • Funds reported $5.5B of Array Biopharma Inc stock for Q1 2019, up 83% quarter-over-quarter.
  • 62 funds opened new Array Biopharma Inc positions in Q1 2019 and 29 closed out, a net change of +33 holders.
  • The largest Array Biopharma Inc buyer in Q1 2019 was T. Rowe Price Associates, an estimated $123M added.
  • The largest Array Biopharma Inc seller in Q1 2019 was Redmile Group, an estimated $114M sold.

Based on aggregated 13F filings for Q1 2019.